Lupin has informed that the Company has received a communication from the US FDA classifying the inspection conducted at its Tarapur manufacturing (API) facility between September 16 to September 20, 2019 as Official Action Indicated (OAI). The inspection at the Tarapur facility had closed with three observations. The Company does not believe that this inspection classification will have an impact on disruption of supplies or the existing revenues from operations of this facility. The Company is in the process of sending further updates of its corrective actions to the US FDA and is hopeful of a positive outcome. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
